In a potential $1 billion-plus deal that Cowen and Co. analyst Eric Schmidt described as "a necessary and favorable solution" for Merrimack Pharmaceuticals Inc.'s financial straits, the company is selling its approved pancreatic cancer drug Onivyde and its generic version of Doxil candidate to Ipsen SA.